The BIO attendance signals potential partnering progress but lacks concrete deal announcements. Monitor for subsequent licensing or collaboration agreements that could materialize post-conference; absent catalysts, neutral sentiment is appropriate for a pre-revenue micro-cap.
Price Chart
Executive Summary
Can-Fite BioPharma announced its participation in the BIO International Convention 2026 (June 22-25) to conduct partnering meetings for its clinical-stage pipeline, including lead candidates Namodenoson (Phase III HCC, Phase IIa pancreatic, Phase IIb MASH) and Piclidenoson (Phase III psoriasis, preparatory Phase II Lowe Syndrome). The company has generated approximately $20M in upfront and milestone payments from prior licensing deals. The press release contains no new clinical data or financial results — it is a routine corporate development update.
Key Facts
- Can-Fite will attend BIO International Convention 2022 June 22–25 in San Diego to conduct partnering meetings
- Lead candidate Namodenoson is in pivotal Phase III for HCC, Phase IIa for pancreatic cancer completed, and Phase IIb for MASH underway
- Piclidenoson is in pivotal Phase III for psoriasis and preparatory work for Phase II in Lowe Syndrome
- Prior licensing agreements have generated approximately $20 million in upfront and milestone payments, with potential for additional milestones and royalties
- Market cap is approximately $6M; stock has been volatile with recent neutral calls showing mixed returns
- No new clinical data, financial results, or material agreements were announced in this release
Financial Impact
No new financial data reported. Prior licensing deals generated approximately $20M in upfront/milestone payments to date.
Risk Factors
- No new clinical data or partnerships announced — pure business development activity with uncertain outcome
- Can-Fite has a history of losses and needs additional capital; stock price is at ~$6M market cap with low liquidity
- Forward-looking statements regarding partnering success may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313305 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.72 | awaiting T+5 | — | $1.65 (−4.07%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.65 (+28.26%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.65 (−24.66%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.65 (−29.79%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.65 (+30.08%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.65 (−53.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers